DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0191271 A1 Brown Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2009/0191271 A1 Brown Et Al US 2009019 1271A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0191271 A1 BrOWn et al. (43) Pub. Date: Jul. 30, 2009 (54) TOPICAL FORMULATIONS (86). PCT No.: PCT/GB2O06/OO3408 (75) Inventors: Marc Barry Brown, Hertfordshire S371 (c)(1), (GB); Stuart Allen Jones, London (2), (4) Date: Jul. 16, 2008 (GB) (30) Foreign Application Priority Data Correspondence Address: Sep. 14, 2005 (GB) ................................... 0518769.5 GREENLEE WINNER AND SULLIVAN PC Publication Classification 4875 PEARL EAST CIRCLE, SUITE 200 (51) Int. Cl. BOULDER, CO 80301 (US) A6IR 9/14 (2006.01) A6II 47/32 (2006.01) (73) Assignee: Med Pharm Limited, Surry (52) U.S. Cl. ...................................... 424/487: 514/772.4 Research Park,Guildford (GB) (57) ABSTRACT Saturated, monophasic Solutions of drug in a solvent and (21) Appl. No.: 12/067,004 propellant mixture, together with a film-forming agent, exhibit transdermal diffusion fluxes greater than those pre (22) PCT Filed: Sep. 14, 2006 dicted by Fick's law when applied topically. Terrary Flot. Formulation 22 Soluble W Precipitated 2 s's 8 S. s 2. s 3:33s E.syster HF / Excipient%) Patent Application Publication Jul. 30, 2009 Sheet 1 of 14 US 2009/0191271 A1 10%PVP Soluble 6) Insoluble Patent Application Publication Jul. 30, 2009 Sheet 2 of 14 US 2009/0191271 A1 20%PWF Soluble 3. Insoluble 00%HFA sweetnews Patent Application Publication Jul. 30, 2009 Sheet 3 of 14 US 2009/0191271 A1 0% VP Soluble & Insoluble 0%BMW Fig.3 Patent Application Publication Jul. 30, 2009 Sheet 4 of 14 US 2009/0191271 A1 -a-30 SHOT, 10% EtOH BDP 4000 --20 SHOT, 10% EtOHBDP 3500 --o- 510 SHOT, SHOT, 10%. 10% EtOHBDP EtOHBDP 70 SO 50 - 4G 05 Shio 30 10%EtOHBDP at BOP Cream Patent Application Publication Jul. 30, 2009 Sheet 5 of 14 US 2009/0191271 A1 450,0 '' --ran 510 Shot shot 20%EtOH 10%EOH 350.0 30, 250.0 200,0 S.O. 10.0 SO, O 0.5 5 2 2.5 3 3.5 4. 45 Time (h) Fig.6 -- BMW Spray, 20 shots 3000 ... BMW Cream 200 O 50. O O.O 50.0 . O Time (h) Fig.7 Patent Application Publication Jul. 30, 2009 Sheet 6 of 14 US 2009/0191271 A1 O00 90.0 80.0 0.0 6.0 500 40,0 30, 2. O, -- BMW Spray, 5 shots -- BMW Mousse O.O O OS 5 2. 3. 3.5 4. 4.5 Time (h) Fig.8 9000 8000 win Saturated PEG 7000 essee 50:50 PWAFW 800,0 500,0 400,0 3000 2000 000 0.0 O O.S .5 2.5 3 3.5 4. 4.5 Time (h) Fig.9 Patent Application Publication Jul. 30, 2009 Sheet 7 of 14 US 2009/0191271 A1 4500 -- Saturated non 4000 Wolatile -- Subsaturated -A-Saturated volatile 30).O 2500 200.0 SOO. O.O 50.0 - O.O. were State EG . -- 0%. EtOH x40, No plastic or 59 FECSx30 . ruru iO% PEG, 40x St. 2X, X. Patent Application Publication Jul. 30, 2009 Sheet 8 of 14 US 2009/0191271 A1 Ternary Flot. Formulation 22 - Soluble W Precipitated g 3:33:3: s mes s es s i: is, Sis J. y re is girls; 8 fs ...Y as A 't s HFA e/ W. 7, *: Excipient%) 3 t 5 f 8 Patent Application Publication Jul. 30, 2009 Sheet 9 of 14 US 2009/0191271 A1 -0-0.013% BMW -- 0.500% BMW | *I 1.00% BMW --sat Etoh - 6O ( 0.013% BMW y: 60.095x + 4,6492 5 O r is 0.500% BMW R = 0.9967 4 O A 1.00% BMW it 42.199x 0.088 x Sat EtOH y Ro 800 3 O y is 23,874x + 11.291 2 O R = 0.6924 O y: 8,488x -3.1394 Rs 0.9979 O 0.2 0.4 0.6 0.8 Patent Application Publication Jul. 30, 2009 Sheet 10 of 14 US 2009/0191271 A1 Ternary Plot, F22 SA Fixed at 2%, Excipient = Copowidone S-630 19 Jul 06 HFA 5 O 15 2O 25 Excipient O Soluble o Precipiated Patent Application Publication Jul. 30, 2009 Sheet 11 of 14 US 2009/0191271 A1 35,0. -- Spray X 3O.O. E. Spray Y miro Spray Z 5s 250 mem. DiproSonew cream al g 8 20.0 - 92 555 15.0 s S. 10.0 - E 3 5.0 - t s 0.0 - 25- raw O 1 2 3 4. 5 Time (h) Patent Application Publication Jul. 30, 2009 Sheet 12 of 14 US 2009/0191271 A1 Ternary Plot, F22 90 HFA (%) Ethanol Fixed at 10%, 10 Excipient = PVP K90 O BPO (%) O O Soluble 5 O Excipientxcipient (%) O Precipiated Patent Application Publication Jul. 30, 2009 Sheet 13 of 14 US 2009/0191271 A1 5,00 4,50 4,00- y = -0.3056x + 3,4968 3,50 - R2 = 0.7195 3.00 - 2,50 - 200 150 100 - 0.50 O,OO . O 2 3 4 5 6 7 8 9 Distance (cm) Fig. 17 y = 0.3394x + 1.809 R = 0,5184 Number of Shots Fig. 18 Patent Application Publication Jul. 30, 2009 Sheet 14 of 14 US 2009/0191271 A1 30,00 . ... MDA -- BMM Gel 2 5. O O 20.00 15.00 10,00 5.00 0.00 immorowo rowroomoro-romaroorooo-oo-oor O 10 20 30 40 50 60 70 80 Time (h) Fig. 19 US 2009/019 1271 A1 Jul. 30, 2009 TOPCAL FORMULATIONS greatly to the epidermal permeability barrier, both to water and to other permeates (Ting et al., 2004). 0005. In order for therapeutic quantities of drug to pen 0001. The present invention relates to formulations for etrate the skin, the barrier properties of the Stratum corneum topical drug delivery, and methods for their use and manufac must be overcome. The Stratum corneum exhibits selective ture. permeability and allows only relatively lipophilic compounds 0002 The administration of therapeutic compounds either with a molecular weight below 400 Daltons to pass. However, locally to the skin, or into the systemic circulation after pas where a drug is very lipophilic, it may cross the Stratum sage through the skin, offers numerous potential advantages corneum, but diffusion is rapidly slowed as it enters the more over oral or parenteral drug delivery. These include the avoid aqueous lower regions of the epidermis in which it is poorly ance of hepatic first-pass metabolism, improved patient com soluble. Thus, as the diffusion of a very hydrophobic perme pliance and ease of access to the absorbing membrane, i.e. the ate proceeds into deeper layers of the skin, diffusion slows, skin. In addition, in the case of local delivery (i.e. delivery to and the concentration gradient (from Stratum corneum down the superficial layers of the skin) by directly administering the to the viable tissue) falls. The rate-determining step for spe drug to the pathological site, any adverse effects associated cies diffusing in this manner then becomes barrier clearance with systemic toxicity can be minimised. However, the effec not barrier penetration. tive delivery of drugs into and through the skin is not trivial. 0006. In addition to their inability to penetrate into the 0003 Molecules can pass into and/or through the skin via deep layers of the epidermis, poorly water soluble molecules passive diffusion. Passive diffusion can be described thermo are also notoriously difficult to formulate as they often exhibit dynamically by Fick's first law: low solubility in numerous topical vehicles. A sufficient con centration of a topically applied therapeutic agent must be loaded into the vehicle to ensure an adequate concentration KD(capp - erec) 1 gradient between the formulation and the skin, in order to attain adequate release of the drug into the skin. Topical formulations, such as ointments, which can solubilise high where (J) describes the steady state flux per unit area, (K) is concentrations of hydrophobic actives, are “heavy” and the partition of the drug between the skin and the formulation 'greasy', thus making them cosmetically unacceptable. and (D) is the diffusion coefficient through the diffusional However, the low solubility of hydrophobic compounds in path length (h). Since usually the concentration of the perme more cosmetically acceptable topical vehicles such as creams ate in the applied dose (c) is so much higher than the and gels often precludes their use. concentration in the receptor phase (c.) this equation can be 0007 Methods of overcoming the barrier properties of the simplified to: Stratum corneum may be divided into chemical. Such as the use of occlusion, penetration enhancers and Supersaturated J-keaf22 2 systems, and physical. Such as iontophoresis, skin electropo where k is the permeability coefficient and equal to KD/h ration, ultrasound and powder injection methods. For Small (Hadgraft, 2004). According to Fick's law the most important organic molecules, chemical enhancement methods have sev factors that influence flux across the skin are the concentra eral advantages, in terms of their low cost, lack of irritancy, tion gradient of the drug within the skin, the partition coeffi and simplicity, compared to physical methods. cient of the permeate and the diffusion coefficient (Thomas 0008 Irrespective of their mode of action, penetration and Finnin, 2004; Hadgraft, 2004). In addition, the flux (J) of enhancers usually alter the barrier properties of the skin. a molecule across a membrane should increase linearly with Whether the structural alteration is reversible or not, the con concentration until c. reaches the solubility limit i.e. at the centrations of penetration enhancers required to elicit an effi point of Saturation (i.e.
Load more

Recommended publications
  • Subject Index
    52_1107_1136_SI 16.11.2005 9:35 Uhr Seite 1107 Subject Index A – tape 264, 368, 940 α-adjustment 154 AAS, see atomic absorption spectrophotometry adrenocorticotrophic hormone (ACTH) 21 abietic acid 909, 943 adverse drug reaction 401 abrasion 174, 283 aeroallergen 391 absorption through appendage 169 – atopic eczema 391 α-acaridial 329 – avoidance 391 accident 889 aerospace 726 acebutolol hydrochloride 909 African aceclofenac 909 –ebony783 acetaldehyde 943 – mahagony 783 acetone 118, 666 – red padauk wood 783 acetylacetone 697 Agave acetylsalicylic acid 84, 909 – americana 354 Achillea millefolium (yarrow extract) 909 – tequilana 225 aciclovir 909 age 279 acid 110 agent orange 806 – black 48 (CI 65005) 909 AGEP 404 – dye 689 Agfa TSS 355 – halogenated 259 aggravation 204 –hydrochloric261 agricultural worker 272 –nitric261 agriculture 725 –red AICD, see activation-induced cell death – – 14 (azorubine) 909 airborne – – 118 (CI 26410) 909 – allergic contact dermatitis 218, 228, 315, 467, 477, 484, 598, ––359909 627, 654, 788 – violet 17 (CI 42650) 909 – contact urticaria 753, 758 – yellow – irritant contact dermatitis 625 – – 36 (CI 13065, metanil yellow) 909 aircraft manufacture 560 – – 61 (CI 18968) 909 airway symptom 520 acitretin 341 alachlor 953 acneiform alantolactone 55, 789, 909, 954 – folliculitis 229 alclometasone-17,21-dipropionate 909 –lesion265 alclometasone-17-propionate 58 acrodermatitis enteropathica 241 alcohol, see also ethyl 909 acrovesicular dermatitis 401 aldehyde 110, 607, 886 acrylamide 592, 944 algicide 562 acrylate
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • 1 J Investig Allergol Clin Immunol 2021; Vol. 31(5) © 2021
    1 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.18176/jiaci.0681 J Investig Allergol Clin Immunol 2021; Vol. 31(5) © 2021 Esmon Publicidad doi: 10.18176/jiaci.0681 2 RESUMEN La prueba de exposición controlada a fármacos (DPT) se considera actualmente el estándar de oro para el diagnóstico de alergia a medicamentos. Las reacciones adversas inducidas por medicamentos (RAM) son un motivo creciente de consulta tanto en atención primaria como especializada. Las consultas de Alergología en España son las que habitualmente estudian estas RAM y descartan mecanismos inmunológicos implicados hasta en el 90% de los casos consultados. Un abordaje adecuado de estos casos repercute de una manera evidente en los costes y la eficacia de los tratamientos requeridos por otros especialistas, de modo que, si no empleáramos los DPT, los pacientes requerían tratamientos más costosos, más tóxicos y menos eficaces en la mayoría de los casos. En los últimos años se han desarrollado un gran número de nuevos fármacos y este documento pretende ser una guía práctica en la gestión de las DPT con la visión de la Sociedad Española de Alergología. El trabajo de diagnóstico comienza con un historial detallado del paciente. Las pruebas cutáneas solo son útiles en algunos medicamentos y, en la mayoría de los casos, el diagnóstico solo puede confirmarse mediante el DPT. Aunque suele haber reactividad cruzada, las DPT pueden confirmar el diagnóstico y también contribuir a encontrar un fármaco alternativo tolerable.
    [Show full text]
  • THI TOETATUTUMUTUALNIHUS009962372B2 (12 ) United States Patent ( 10 ) Patent No
    THI TOETATUTUMUTUALNIHUS009962372B2 (12 ) United States Patent ( 10 ) Patent No. : US 9 , 962, 372 B2 Milanese et al. (45 ) Date of Patent: May 8 , 2018 ( 54 ) PHARMACEUTICAL COMPOSITION FOR ( 56 ) References Cited THE TREATMENT OF MYCOSIS U . S . PATENT DOCUMENTS (71 ) Applicant: AZIENDE CHIMICHE RIUNITE 2004 / 0180965 A1 * 9/ 2004 Borgman . .. .. A61K 9 /0034 ANGELINI FRANCESCO A . C . R . A . F . 514 /649 S . p . A ., Rome ( IT ) 2009/ 0208558 AL 8 / 2009 Noe et al . ( 72 ) Inventors : Claudio Milanese , Rome ( IT ) ; FOREIGN PATENT DOCUMENTS Alessandra Capezzone De Joannon , Rome ( IT ) ; Serena Tongiani, Genzano WO 96 / 26724 AL 9 / 1996 di Roma (IT ) ; Luca Donati , Porto San Giorgio ( IT ) OTHER PUBLICATIONS Rani et al. Mini- reviews in Medicinal chemistry, 2013 , 13 ( 11) , @( 73 ) Assignee : AZIENDE CHIMICHE RIUNITE 1626 - 1655 (abstract ) .* ANGELINI FRANCESCO A . C . R . A . F . Yucesoy et al. , “ In -vitro Synergistic Effect of Fluconazole with S . p . A . , Rome (IT ) Nonsteroidal Anti - Inflammatory Agents Against Candida albicans Strains” , Journal of Chemotherapy, vol. 12 , No . 5 , 2000 , p . 385 - 389 , XP 002429141 . @( * ) Notice : Subject to any disclaimer, the term of this Boselli et al . , “ Efficacy and Tolerability of Fitostimoline ( Vaginal patent is extended or adjusted under 35 Cream , Ovules , and Vaginal Washing ) and of Benzydamine Hydro U . S . C . 154 (b ) by 0 days . days . chloride ( Tantum Rosa Vaginal Cream and Vaginal Washing ) in the Topical Treatment of Symptoms of Bacterial Vaginosis ” , ISRN Obstetrics and Gynecology, vol. 2012 , 2012 , p . 1 - 5 . (21 ) Appl . No. : 15 /541 , 245 EUCAST, “ EUCAST Definitive Document EDef 7 . 1 : method for @I the determination of broth dilution MICs of antifungal agents for ( 22 ) PCT Filed : Jan .
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,664.224 B2 Shirouzu Et Al
    USOO8664224B2 (12) United States Patent (10) Patent No.: US 8,664.224 B2 Shirouzu et al. (45) Date of Patent: Mar. 4, 2014 (54) EXTERNAL PREPARATION FOR ATHLETES FOREIGN PATENT DOCUMENTS FOOT TREATMENT EP O71585.6 A1 6, 1996 EP 1532.977 A1 5, 2005 (75) Inventors: Toshihiro Shirouzu, Tosu (JP): Youichi JP O3-038522 2, 1991 Kawamura, Tosu (JP); Hiroki JP O7-223971 8, 1995 Kawatsura, Tosu (JP); Mitsuhiko JP O7-233O88 9, 1995 Tokunaga, Tosu (JP) JP 08-020527 1, 1996 JP 08-151324 6, 1996 JP 09-176014 7/1997 (73) Assignee: Hisamitsu Pharmaceutical Co., Inc., JP 10-265377 10, 1998 Tosu-Shi, Saga (JP) JP 2001-1288O1 5, 2000 JP 2002-2847O2 * 10/2002 (*) Notice: Subject to any disclaimer, the term of this JP 2004-035411 2, 2004 patent is extended or adjusted under 35 JP 2004-1495.08 5, 2004 WO WO99.49835 A1 10, 1999 U.S.C. 154(b) by 0 days. WO WOO1/95718 A1 12/2001 (21) Appl. No.: 13/183,621 OTHER PUBLICATIONS (22) Filed: Jul. 15, 2011 Ali-Shtayeh et al. "Antimicrobial Activity of Micromeria nervosa from the Palestinian Area” Journal of Ethnopharmacology 1997 (65) Prior Publication Data 58:143-147. Encyclopaedia Chimica, Kagaku Daijiten 5 reduced-size edition, US 2011 FO269794 A1 Nov. 3, 2011 Kagaku Daijiten Henshu Iinkai eds., Kyoritsu Shuppan Co., Ltd., Feb. 15, 1987, p. 909. Related U.S. Application Data Database WPI Week 200306 Derwent Publications Ltd., London, (63) Continuation of application No. 12/338,096, filed on GB, AN 2003-0601 14 and CN 1368-51 (Tang Y.) Sep.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Anti-Fungal Agent Antimykotischer Wirkstoff Agent Antifongique
    (19) TZZ _¥_T (11) EP 2 762 139 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4178 (2006.01) A61P 31/10 (2006.01) 13.04.2016 Bulletin 2016/15 C07D 409/06 (2006.01) (21) Application number: 12836654.9 (86) International application number: PCT/JP2012/074580 (22) Date of filing: 25.09.2012 (87) International publication number: WO 2013/047530 (04.04.2013 Gazette 2013/14) (54) ANTI-FUNGAL AGENT ANTIMYKOTISCHER WIRKSTOFF AGENT ANTIFONGIQUE (84) Designated Contracting States: (56) References cited: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • YASUKO NANJO ET AL.: ’In vitro Antifungal GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Activities of Clinically Available Topical PL PT RO RS SE SI SK SM TR Antifungal Drugs’ JAPANESE JOURNAL OF DERMATOLOGYvol. 117, no. 2, 20 February 2007, (30) Priority: 26.09.2011 JP 2011209903 pages 149 - 152, XP008173701 • NIWANO Y ET AL.: ’Efficacy of NND-502, a novel (43) Date of publication of application: imidazole antimycotic agent, in experimental 06.08.2014 Bulletin 2014/32 models of Candida albicans and Aspergillus fumigatus infections’ INTERNATIONAL (73) Proprietor: Nihon Nohyaku Co., Ltd. JOURNAL OF ANTIMICROBIAL AGENTS vol. 12, Tokyo 104-8386 (JP) no. 3, August 1999, pages 221 - 228, XP055104990 • SHIGERU ABE ET AL.: ’Anti-Candida Activities of (72) Inventors: Azole Antifungals in the Presence of Lysozyme • KOGA, Hiroyasu In Vitro’ JAPANESE JOURNAL OF MEDICAL Kawachinagano-shi MYCOLOGY vol. 39, no.
    [Show full text]
  • Biol. Pharm. Bull. 29(5) 919—922 (2006) 919
    May 2006 Biol. Pharm. Bull. 29(5) 919—922 (2006) 919 Effects of Antifungal Drugs on Proliferation Signals in Candida albicans Mitsuo MATSUKI, Hatsuki KANATSU, Toshihiko WATANABE,* Ayako OGASAWARA, Takeshi MIKAMI, and Tatsuji MATSUMOTO Department of Microbiology, Tohoku Pharmaceutical University; 4–4–1 Komatsushima, Aoba-ku, Sendai 981–8558, Japan. Received October 25, 2005; accepted February 2, 2006; published online February 6, 2006 The sensitivity of Candida albicans to antifungal drugs when cultured under aerobic and anaerobic condi- tions was measured. Ciclopirox olamine and siccanin were more effective under aerobic than under anaerobic conditions. Terbinafine, neticonazole and amphotericin B showed the same antifungal activity under both aero- bic and anaerobic conditions. None of these antifungal activities were affected by the pH conditions. Terbinafine inhibited the elongation of hyphae, while neticonazole and amphotericin B induced proliferation of the yeast form. The expression of RAS1, EFG1 and CPH1 mRNAs was inhibited by these drugs. These results suggested that the inhibition of hyphal formation might be caused by disruption of the RAS1-signal pathway. Key words Candida albicans; ciclopirox olamine; siccanin; terbinafine; neticonazole; amphotericin B Candida albicans is an opportunistic fungus which gener- graphing the cultures with a camera attached to an IX51 mi- ally exists in the oral cavity, skin, vagina and intestinal or- croscope (Olympus). gans, and is also one of the causes of superinfection.1) The Quantification of mRNAs in C. albicans C. albicans antifungal drugs described below are applied to treat superfi- (1ϫ105 cells/ml in RPMI1640 medium) was incubated at cial and deep-seated infections. 37 °C for 6 h under 5% CO2.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0287064 A1 Swenholt (43) Pub
    US 20140287O64A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0287064 A1 SWenholt (43) Pub. Date: Sep. 25, 2014 (54) COMPOSITIONS FOR IMPROVING THE Publication Classification APPEARANCE AND/OR TREATING FUNGAL INFECTIONS OF NAILS, MUCUS (51) Int. Cl. MEMBRANES AND THE INTEGUMENT A633/20 (2006.01) A61E36/87 (2006.01) (71) Applicant: Karen G. Swenholt, Annandale, VA A6II 45/06 (2006.01) (US) A63L/05 (2006.01) A61E36/534 (2006.01) (72) Inventor: Karen G. Swenholt, Annandale, VA A61E36/63 (2006.01) (US) A61E36/53 (2006.01) (52) U.S. Cl. CPC ................. A61 K33/20 (2013.01); A61K 36/63 (21) Appl. No.: 14/120,510 (2013.01); A61 K36/87 (2013.01); A61K 36/53 (2013.01); A61 K3I/05 (2013.01); A61 K 36/534 (2013.01); A61K 45/06 (2013.01) (22) Filed: May 28, 2014 USPC .......................................................... 424/665 (57) ABSTRACT Related U.S. Application Data Fungal infections and other disease conditions of the integu (63) Continuation-in-part of application No. 13/507,871, ment can be effectively treated with compositions containing filed on Aug. 3, 2012, Continuation-in-part of applica oZonizable oils, plant extract oils and antimicrobials, when tion No. 12/587,495, filed on Oct. 7, 2009, Continu used in conjunction with Solutions containing sodium chlo ation-in-part of application No. 12/387,119, filed on rite. The compositions are particularly useful for treatment of Apr. 28, 2009, now abandoned. resistant fungal infections. US 2014/0287O64 A1 Sep. 25, 2014 COMPOSITIONS FOR IMPROVING THE inhibits the growth of a multitude of fungi known to cause APPEARANCE AND/OR TREATING FUNGAL onychomycosis (Phytother Res.
    [Show full text]